Elevance Health (ELV) earnings call transcript summary & sentiment

Our read on the 15 July 2026 earnings call

Overall tone

Positive

Executive Summary

Elevance Health delivered second-quarter performance ahead of expectations, prompting management to raise full-year 2026 adjusted diluted EPS guidance to at least $27.00 and re-establish an earnings modeling baseline of at least $26.00 for 12%+ EPS growth in 2027.

Core Signals

Revenue Growth & Demand: Operating revenue rose 0.8% year-over-year to $49.8 billion, driven by higher premium yields and product revenue that offset fee-based membership transitions.

Bullish Signals

Full-year 2026 adjusted diluted EPS guidance raised to at least $27.00 alongside reaffirmed target of 12%+ EPS growth in 2027.

Risk Signals

Medicaid operating margin outlook remains depressed at negative 1.75% for 2026 due to elevated utilization among remaining members.

Q&A Signals

Repeated analyst topics: Analysts repeatedly focused on Medicaid rate alignment, state market exit criteria, and utilization variance across lines of business.

Key Investor Debate

The key investor debate revolves around whether 2026 represents the true financial trough for Elevance's Medicaid segment and how rapidly margins will normalize toward target levels.

Analyst Takeaway

Elevance demonstrated disciplined operating execution, effectively leveraging Medicare Advantage plan design adjustments and commercial pricing power to absorb Medicaid headwinds.